This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.
—The principal investigators of the Collaborative Corneal Transplantation Studies (CCTS), a National Eye Institute-sponsored multicentered clinical trial of histocompatibility matching in high-risk keratoplasty, have received several inquires regarding our position on recommendations for tissue matching and sharing of typed tissue.We believe that the available data do not, at this time, allow us to determine whether histocompatibility matching improves the prognosis for penetrating keratoplasty in high-risk recipients. Available data do not allow us to determine whether histocompatibility matching, if effective, should be based on HLA-A matches, HLA-B matches, HLA-DR matches, or ABO matches. It is the purpose of the CCTS to address these and other questions.The CCTS is a masked, prospective, randomized clinical trial. Consequently, none of the investigators is aware of the degree of tissue match that any of his patients receive. Data are reviewed biannually by the CCTS Data and Safety Monitoring Committee. At
Stark WJ, Stulting RD, Meyer RF, et al. Sharing Tissue Typing Information From the Collaborative Corneal Transplantation Studies. Arch Ophthalmol. 1989;107(5):633. doi:10.1001/archopht.1989.01070010651004
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: